Palleiko Benjamin L 4
4 · KalVista Pharmaceuticals, Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Palleiko Benjamin L
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-11-17+9,364→ 408,345 total - Exercise/Conversion
Restricted Stock Unit
2025-11-17−2,419→ 4,838 total→ Common Stock (2,419 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-11-17−6,945→ 0 total→ Common Stock (6,945 underlying) - Sale
Common Stock
2025-11-18$14.48/sh−4,466$64,665→ 403,879 total
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.16 to $14.4835 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.
- [F5]1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.